Pelin Esme1, Gulsen Akoglu1, Ercan Caliskan1. 1. Department of Dermatology and Venereology, Gulhane School of Medicine, University of Health Sciences, Ankara, Turkey.
Abstract
INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of hair follicles which usually affects patients' quality of life negatively. Although there are various therapeutic approaches including topical and systemic antibiotics, retinoids, biological agents, and also surgical modalities, there is no curative treatment option and clinical management of HS is still challenging. CASE PRESENTATION: Herein, we present a 43 year-old man with HS who had used different treatments in 15 years. The patient showed improvement initially with adalimumab, then exhibited secondary unresponsiveness after 18 months. While worsening of HS was recorded due to increased discharge under secukinumab, no additional benefit was observed with methotrexate. He was not willing to undergo surgical procedures due to previous surgical experience. Finally, certolizumab pegol has been started to patient with similar dosing to psoriasis patients. Sartorius, 10-point visual analogue scale (VAS), and dermatological life quality index (DLQI) scores regressed from 171 to 105, 9/10 to 3/10, and 27 to 19 after 3 months with certolizumab pegol treatment. DISCUSSION/ CONCLUSION: Certolizumab pegol is a humanized antigen-binding fragment of a monoclonal antibody which binds to TNF-alpha. However, certolizumab pegol is only approved for plaque psoriasis in dermatology; it is likely to be a promising effective agent for HS, especially in challenging cases.
INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of hair follicles which usually affects patients' quality of life negatively. Although there are various therapeutic approaches including topical and systemic antibiotics, retinoids, biological agents, and also surgical modalities, there is no curative treatment option and clinical management of HS is still challenging. CASE PRESENTATION: Herein, we present a 43 year-old man with HS who had used different treatments in 15 years. The patient showed improvement initially with adalimumab, then exhibited secondary unresponsiveness after 18 months. While worsening of HS was recorded due to increased discharge under secukinumab, no additional benefit was observed with methotrexate. He was not willing to undergo surgical procedures due to previous surgical experience. Finally, certolizumab pegol has been started to patient with similar dosing to psoriasis patients. Sartorius, 10-point visual analogue scale (VAS), and dermatological life quality index (DLQI) scores regressed from 171 to 105, 9/10 to 3/10, and 27 to 19 after 3 months with certolizumab pegol treatment. DISCUSSION/ CONCLUSION: Certolizumab pegol is a humanized antigen-binding fragment of a monoclonal antibody which binds to TNF-alpha. However, certolizumab pegol is only approved for plaque psoriasis in dermatology; it is likely to be a promising effective agent for HS, especially in challenging cases.
Authors: L Prussick; B Rothstein; D Joshipura; A Saraiya; Y Turkowski; R Abdat; A Alomran; P Zancanaro; C Kachuk; N Dumont; A B Gottlieb; D Rosmarin Journal: Br J Dermatol Date: 2019-05-12 Impact factor: 9.302
Authors: J R Ingram; F Collier; D Brown; T Burton; J Burton; M F Chin; N Desai; T E E Goodacre; V Piguet; A E Pink; L S Exton; M F Mohd Mustapa Journal: Br J Dermatol Date: 2019-03-11 Impact factor: 9.302
Authors: Alan Menter; Bruce E Strober; Daniel H Kaplan; Dario Kivelevitch; Elizabeth Farley Prater; Benjamin Stoff; April W Armstrong; Cody Connor; Kelly M Cordoro; Dawn M R Davis; Boni E Elewski; Joel M Gelfand; Kenneth B Gordon; Alice B Gottlieb; Arthur Kavanaugh; Matthew Kiselica; Neil J Korman; Daniela Kroshinsky; Mark Lebwohl; Craig L Leonardi; Jason Lichten; Henry W Lim; Nehal N Mehta; Amy S Paller; Sylvia L Parra; Arun L Pathy; Reena N Rupani; Michael Siegel; Emily B Wong; Jashin J Wu; Vidhya Hariharan; Craig A Elmets Journal: J Am Acad Dermatol Date: 2019-02-13 Impact factor: 11.527
Authors: C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec Journal: J Eur Acad Dermatol Venereol Date: 2015-01-30 Impact factor: 6.166
Authors: Peter C M van de Kerkhof; Christopher E M Griffiths; Kristian Reich; Craig L Leonardi; Andrew Blauvelt; Tsen-Fang Tsai; Yankun Gong; Jiaqing Huang; Charis Papavassilis; Todd Fox Journal: J Am Acad Dermatol Date: 2016-05-12 Impact factor: 11.527
Authors: Rachel G Casseres; Lisa Prussick; Pedro Zancanaro; Brooke Rothstein; Deep Joshipura; Ami Saraiya; Yana Turkowski; Shiu Chung Au; Abdulaziz Alomran; Rana Abdat; Minawaer Abudu; Courtney Kachuk; Nicole Dumont; Alice B Gottlieb; David Rosmarin Journal: J Am Acad Dermatol Date: 2020-02-07 Impact factor: 11.527
Authors: Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec Journal: N Engl J Med Date: 2016-08-04 Impact factor: 91.245
Authors: Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin Journal: J Am Acad Dermatol Date: 2019-03-11 Impact factor: 15.487